TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.940
-0.040 (-2.02%)
At close: Dec 5, 2025, 4:00 PM EST
1.980
+0.040 (2.06%)
After-hours: Dec 5, 2025, 7:50 PM EST
TuHURA Biosciences Employees
TuHURA Biosciences had 19 employees as of December 31, 2024. The number of employees increased by 18 or 1,800.00% compared to the previous year.
Employees
19
Change (1Y)
18
Growth (1Y)
1,800.00%
Revenue / Employee
n/a
Profits / Employee
-$1,541,833
Market Cap
99.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HURA News
- 22 days ago - TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 4 weeks ago - TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition - PRNewsWire
- 3 months ago - TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference - PRNewsWire
- 4 months ago - TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 5 months ago - Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development - GlobeNewsWire
- 5 months ago - TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - PRNewsWire
- 5 months ago - TuHURA Biosciences Completes Acquisition of Kineta - PRNewsWire
- 5 months ago - TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma - PRNewsWire